| Title |
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
|
|---|---|
| Published in |
Diabetes Therapy, April 2018
|
| DOI | 10.1007/s13300-018-0422-4 |
| Pubmed ID | |
| Authors |
Riccardo Candido, Kathleen Wyne, Ester Romoli |
| Abstract |
Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities. Eli Lilly and Company. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 30% |
| United Kingdom | 2 | 20% |
| Paraguay | 1 | 10% |
| France | 1 | 10% |
| Unknown | 3 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 98 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 19% |
| Student > Master | 17 | 17% |
| Researcher | 9 | 9% |
| Other | 6 | 6% |
| Student > Doctoral Student | 5 | 5% |
| Other | 6 | 6% |
| Unknown | 36 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 13% |
| Nursing and Health Professions | 9 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Other | 13 | 13% |
| Unknown | 38 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2023.
All research outputs
#5,300,322
of 24,963,265 outputs
Outputs from Diabetes Therapy
#245
of 1,123 outputs
Outputs of similar age
#94,487
of 333,693 outputs
Outputs of similar age from Diabetes Therapy
#9
of 39 outputs
Altmetric has tracked 24,963,265 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,123 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,693 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.